Novel dose-finding designs and considerations on practical implementations in oncology clinical trials
Authors:
- 3 June 2016
- journal article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 27 (1) , 44-55
Abstract
One of the main objectives in phase I oncology trials is to evaluate safety and tolerability of an experimental treatment by estimating the maximum tolerated dose (MTD) based on the rate of dose-limiting toxicities (DLT). To meet emerging challenges in dose-finding studies, over the past two decades, extensive research has been conducted by statistical and medical researchers to create innovative dose finding designs that perform better than the standard 3 + 3 design, which often exhibits undesirable statistical and operational properties. However, clinical implementation and practical usage of these new designs have been limited. This article begins with a review of the most recent literature and then provides some perspectives on implementing novel adaptive dose finding designs in oncology phase I trials from a pharmaceutical industry perspective. Statistical planning and logistical considerations on how to effectively execute such designs in multi-center clinical trials are discussed using two recent case studies.Keywords
This publication has 47 references indexed in Scilit:
- Dose Finding by the Continual Reassessment Method2011
- Designs for dose–escalation trials with quantitative responsesStatistics in Medicine, 2009
- Monitoring late-onset toxicities in phase I trials using predicted risksBiostatistics, 2007
- Simultaneously optimizing dose and schedule of a new cytotoxic agentClinical Trials, 2007
- Coherence principles in dose-finding studiesBiometrika, 2005
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma TrialJournal of the American Statistical Association, 2004
- The bivariate continual reassessment methodControlled Clinical Trials, 2002
- Sequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesBiometrics, 2000
- Cancer phase I clinical trials: efficient dose escalation with overdose controlStatistics in Medicine, 1998
- The continual reassessment method in cancer phase i clinical trials: A simulation studyStatistics in Medicine, 1993